Enpatoran - Merck KGaA
Alternative Names: M-5049Latest Information Update: 28 Mar 2024
At a glance
- Originator EMD Serono Research & Development Institute; Merck KGaA
- Class Amines; Anti-inflammatories; Antivirals; Nitriles; Piperidines; Quinolines; Skin disorder therapies; Small molecules
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 pneumonia; Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Systemic lupus erythematosus
- Phase I Unspecified
- No development reported Immunological disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Cutaneous-lupus-erythematosus in Ukraine (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Cutaneous-lupus-erythematosus(In the elderly, In adults) in Macedonia (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Ukraine (PO)